---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-25-000046"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:54:56.376851+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q3 sales $5.065B (+20.3% reported) beat guidance; adjusted EPS $0.75 beats $0.70-0.72

## Summary
- GAAP net income $755M ($0.51 EPS) vs $469M ($0.32) a year ago; adjusted EPS $0.75 vs $0.63.
- Cardiovascular sales $3.343B (+22.4% reported); MedSurg $1.722B (+16.4%).
- U.S. sales +27.0% reported; EMEA +2.6% reported but -2.0% operational due to ACURATE discontinuation.
- FY2025 guidance: reported sales growth ~20%, organic ~15.5%; GAAP EPS $1.97-2.01, adjusted EPS $3.02-3.04.
- Agreed to acquire Nalu Medical (neuromodulation) and acquired Elutia's antibiotic-eluting Envelope products.

## SEC filing metadata
- accession: 0000885725-25-000046
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572525000046/0000885725-25-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572525000046/bsx-20251022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-25-000046
- JSON: https://secwatch.observer/filing/0000885725-25-000046.json
- Plain text: https://secwatch.observer/filing/0000885725-25-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.